為連續性腎臟替代迴路局部檸檬酸鹽抗凝替代液，適用於接受 CRRT 治療且適合 RCA 的成年患者。每袋含有鈉 (140 mmol/L)、氯化物 (86 mmol/L) 和低濃度的檸檬酸鹽 (18 mmol/L)。

Anticoagulant

Metabolism: Primarily hepatic.
Excretion: Urine.

Hypersensitivity to sodium chloride, sodium citrate, or any component of the formulation; severe liver failure; shock with muscle hypoperfusion.

Frequency not defined: hypotension, fluid volume disorder, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hypophosphatemia, metabolic acidosis, metabolic alkalosis.

Replacement solution for regional citrate anticoagulation of continuous renal replacement circuit:
Rate of solution administered depends upon the targeted citrate dose and the prescribed blood flow rate. Prefilter infusion rate is indexed to the blood flow rate to achieve a target blood citrate concentration of 3 to 4 mmol/L. Flow rate for anticoagulation of the extracorporeal circuit should be titrated to achieve a post-filter ionized calcium concentration of 0.25 to 0.35 mmol/L.

No dosage adjustment necessary.

Mild to moderate impairment:dosage reduction may be needed; monitor closely for citrate accumulation.
Severe impairment: contraindicated in patients with severe failure; avoid use in patients with reduced liver and muscle perfusion (eg, patients with lactic acidosis or septic shock).